Robert Lafyatis is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
725 Albany St
Shapiro 7 Suite B
Boston, MA 021183549
Telephone
617-638-7460Registry record last updated 24 May 2021.
Clinical trials
- Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis
Sponsor: Bristol-Myers Squibb
- Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Sponsor: Robert Lafyatis
- Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
Sponsor: Prism Pharma Co., Ltd.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20259 payments
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20252 payments
- ABBVIE INC.Program year20245 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
44.3%Proton pump inhibitor18.4%Pantoprazole Sodium67%Omeprazole33%Part D<11 patientsCorticosteroid14.9%Prednisone100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
40.4%Folate Analog Metabolic Inhibitor25%Methotrexate100%Part D≥13 patientsTNF inhibitor15.4%Humira(Cf) Pen69%Enbrel31%Part D<11 patientsAntiparasitic
10.1%Antimalarial10.1%Hydroxychloroquine Sulfate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
10 NIH research awards on record, funded 1995–2015 per NIH RePORTER. The latest:
- Project 1 Biomarkers of disease activity and progression in systemic sclerosis
Boston University Medical Campus
FY2015$285,007P50AR060780
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”